Comprehensive organic profiling of biological particles derived from blood

Cheng-Yeu Wu1,2,3, Jan Martel1,2,4 & John D. Young1,2,4,5

Mineral nanoparticles form in physiological and pathological processes occurring in the human body. The calcium phosphate mineral phase of the particles has affinity for proteins and lipids, but the complete profiling of the organic molecules that bind to the particles has not been described in detail. We report here a comprehensive analysis of organic components found in mineralo-organic particles derived from body fluids. Based on biological staining, fluorescent tagging, proteomics and metabolomics, our results indicate that the mineral particles bind to proteins, amino acids, carbohydrates, polysaccharides, phospholipids, fatty acids, DNA and low molecular weight metabolites. These results can be used to study the formation and effects of mineralo-organic particles in biological fluids.

Mineral nanoparticles (NPs) have been shown to form in human biological fluids when the concentration of calcium, carbonate and phosphate ions exceeds saturation1–19. These mineral particles represent the first mineral that forms in bones and teeth, as well as in ectopic calcifications and kidney stones13. The particles have been detected in the body fluids and tissues of patients suffering from various conditions, including atherosclerosis, chronic kidney disease and type 2 diabetes5,13. As such, the particles represent precursors of physiological and pathological mineralization processes that occur in the human body.

Recent studies indicate that the mineral particles participate in other physiological roles in vivo. For instance, the particles form in the lumen of human intestines where they bind to dietary antigens and bacteria-derived molecules such as peptidoglycan; the particles in turn present these molecules to macrophages and dendritic cells of the intestinal mucosa to induce immunological tolerance against food and the gut microbiota20. Similar mineral particles called calciprotein particles (CPPs) have also been detected in ruptured fetal membranes from idiopathic preterm birth, suggesting that the particles may also affect human fertility and fetal development21.

We suggested earlier that mineral particles forming in the human body may influence physiological processes by binding to various organic molecules in biological fluids13. Accordingly, proteins bind to the particles and form a “protein corona”, possibly influencing the levels of these proteins in biological fluids. Identification of the molecules that bind to the mineral particles is needed to assess the effects of the particles’ organic components in vivo. Based on various techniques including biological staining, fluorescent tagging, electrophoresis, chromatography, proteomics and metabolomics, we present here a comprehensive analysis of the organic corona of mineral particles formed in bovine and human serum.

Methods
Preparation of particles. The use of human body fluids was approved by the Institutional Review Board of Linkou Chang Gung Memorial Hospital. Written informed consent was obtained from the healthy volunteers who provided the samples. The experiments were performed in accordance with the relevant guidelines and regulations. Human blood was withdrawn and serum was prepared as described before2. Particles were prepared by adding 3 mM of CaCl2 and Na2HPO4 each to Dulbecco’s modified Eagle’s medium (DMEM; Gibco; final volume of 1 ml) containing or not 10% (v/v) fetal bovine serum (FBS; Biological Industries) or human serum (HS). Following incubation in cell culture conditions overnight, the particles were centrifuged at 16,000 × g for

1Laboratory of Nanomaterials, Chang Gung University, Taoyuan, Taiwan. 2Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan. 3Research Center of Bacterial Pathogenesis, Chang Gung University, Taoyuan, Taiwan. 4Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. 5Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan. Cheng-Yeu Wu and Jan Martel contributed equally to this work. Correspondence and requests for materials should be addressed to J.D.Y. (email: jdyoung@mail.cgu.edu.tw)
incubated for 30 min at room temperature. After staining, particles were collected by centrifugation and washed (Merck Millipore) in 100 ml of isopropanol in a warm water bath. The staining solution was prepared by mixing water (50:30:8:2). Staining was performed with iodine vapor.

Macherey-Nagel). Lipids were separated in a tank containing a solution of chloroform/methanol/acetic acid/.

were submitted to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein staining

hrs, and probed with 15 ml of PBS containing 0.2

phosphate buffered saline (PBS) containing 0.05% (v/v) Tween 20 and 3% (w/v) BSA at room temperature for 2

Particles were treated with EDTA, and the solution (20 μl) was transferred to polyvinylidene difluoride (PVDF)

membranes using a dot blot apparatus (Bio-Rad). PVDF membranes were incubated into a blocking solution of phosphatase buffered saline (PBS) containing 0.05% (v/v) Tween 20 and 3% (w/v) BSA at room temperature for 2 hrs, and probed with 15 ml of PBS containing 0.2 μg of biotinylated wheat germ agglutinin (WGA; Sigma) at room

Electron microscopy and spectroscopy analyses. Electron microscopy and spectroscopy analyses were performed as before3. Briefly, washed samples were deposited on Formvar carbon-coated grids and excess water was removed. Dried samples were observed under a field-emission S-5000 scanning electron microscope (Hitachi). Energy-dispersive X-ray spectroscopy (EDX) was performed using an EMX Energy EX-400 EDX device and the software provided by the manufacturer (Horiba). For Fourier-transform infrared (FTIR) spectroscopy, dried samples were mixed 1:100 (w/w) with KBr and analyzed using a Nicolet 5700 FTIR spectrometer (Thermo Fisher Scientific). For Raman spectroscopy, dried samples were examined using the inVia Raman confocal microscope (Renishaw) equipped with a 50 × objective and a charge-coupled device detector. For X-ray diffraction analysis, dried samples were studied using the D5005 X-ray diffractometer (Bruker) and the obtained spectra were compared with the Joint Committee on Powder Diffraction and Standards.

Coomassie blue staining. Particles (50μl) were mixed with 50μl of Coomassie blue staining solution (0.1% w/v Coomassie Brilliant Blue R-250, Sigma; 50% v/v methanol and 10% v/v glacial acetic acid), followed by gentle mixing using the Intelli-Mixer RM2 (Elmi) for 30 min at room temperature. The solution was centrifuged at 16,000 × g for 10 min, and the pellet was resuspended in 500μl of destaining solution (50% v/v methanol, 10% v/v acetic acid). The solution was mixed for 30 min as above. Destained particles were collected by centrifugation and washed three times with water. Particles were resuspended in 20μl of water, and 10μl of the solution was deposited onto a glass slide, covered with a cover slip, and observed under a BX-51 optical microscope (Olympus).

Oil red O staining. A stock solution of oil red O stain was prepared by dissolving 0.5 g of oil red O dye (Merck Millipore) in 100 ml of isopropanol in a warm water bath. The staining solution was prepared by mixing 30 ml of the stock solution with 20 ml of water. The solution was allowed to stand at room temperature for 10 min, prior to filtration into a Coplin jar. The oil red O staining solution (50 μl) was mixed with particles (50μl) and incubated for 30 min at room temperature. After staining, particles were collected by centrifugation and washed three times with water. Particles were resuspended in 20μl of double-distilled water and observed using optical microscopy.

Alcian blue staining. The staining solution was prepared by dissolving 1 g of alcian blue 8GX (A5268, Sigma) in 100 ml of 3% (v/v) glacial acetic acid. The pH was adjusted to 2.5 and the solution was filtered into a Coplin jar. The alcian blue staining solution (50μl) was mixed with 50μl of particles, and the solution was incubated with gentle agitation for 30 minutes at room temperature. Particles were collected by centrifugation and washed three times with water, prior to observation under optical microscopy.

SYBR gold staining. The SYBR gold nucleic acid staining solution (S11494, Invitrogen) was diluted in water (2.5μl of the 10,000 × SYBR solution into 1 ml of water). An aliquot of the solution (30μl) was mixed with particles (30μl) and incubated with gentle agitation for 30 min at room temperature in the dark. After staining, the particles were collected by centrifugation and washed three times with water. The particles were resuspended in water (20μl). Microscopic observations were conducted with an epi-fluorescence microscope (AX70, Olympus) using a blue broad-band filter for excitation (488 nm).

Binding assays. Bovine serum albumin (BSA; 10 mg; Sigma) was dissolved in 1 ml of water and stored at −20°C before use. Phosphatidylethanolamine (25 mg; Sigma) was dissolved in 2 ml of chloroform; the solution was dried in a vacuum centrifuge, and 10 ml of water was added, prior to mixing (final concentration of 5 mg/ml). Xanthan gum (0.5 mg; Sigma) was dissolved into 1 ml of water. Salmon sperm DNA (0.3 g; Sigma) was dissolved into 30 ml of water with gentle mixing for 4 hrs at room temperature. Residues were dispersed using a syringe with a 18 G needle. Water was added to obtain a final concentration of 1 mg/ml of DNA.

Particles were also prepared by adding 3 mM of CaCl2 and Na2HPO4 each to DMEM (1 ml, final volume) containing 0.1 to 100 μg of BSA, as well as FBS (10%), phosphatidylethanolamine (25–250 μg), xanthan gum (0.04–20 μg), or salmon sperm DNA (1–30 μg). Following incubation in cell culture conditions for 30 min, the particles were pelleted and washed with 20 mM HEPES buffer (1 ml), prior to resuspension in 50 μl of 50 mM EDTA.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Washed particles were resuspended in EDTA and mixed with 4 × sample denaturing buffer (15 μl), prior to heating at 95°C for 10 min. Samples (10 μl) were submitted to 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein staining was done with Coomassie blue as described earlier3.

Thin-layer chromatography. Particles were prepared as above using DMEM (1 ml) containing 10% FBS or 25–250 μg of phosphatidylethanolamine were washed and resuspended in EDTA. The solution (20 μl) was loaded onto a 10 cm × 10 cm pre-coated thin-layer chromatography sheet (Alugram Xtra SIL G/UV254, Macherey-Nagel). Lipids were separated in a tank containing a solution of chloroform/methanol/acetic acid/water (50:30:8:2). Staining was performed with iodine vapor.

Dot blotting. Particles were prepared as above, using DMEM (1 ml) containing 0.04–20 μg of xanthan gum. Particles were treated with EDTA, and the solution (20 μl) was transferred to polyvinylidene difluoride (PVDF) membranes using a dot blot apparatus (Bio-Rad). PVDF membranes were incubated into a blocking solution of phosphate buffered saline (PBS) containing 0.05% (v/v) Tween 20 and 3% (w/v) BSA at room temperature for 2 hrs, and probed with 15 ml of PBS containing 0.2 μg of biotinylated wheat germ agglutinin (WGA; Sigma) at room
temperature for 1 hr. After two washing steps using 20 ml of blocking solution containing 1% (w/v) of BSA for 5 min, the PVDF membranes were incubated with 15 ml of blocking buffer containing streptavidin-horseradish peroxidase (HRP) antibody (ab7403, Abcam; 1:25,000) at room temperature with gentle agitation for 30 min. Membranes were washed four times with 20 ml of blocking solution. Signal was revealed with 1 ml of lumino enhancer solution (Promega) based on instructions provided by the manufacturer. Signal was revealed using X-ray radiographic films.

**Agarose gel electrophoresis.** Particles were prepared as above, using DMEM (1 ml) containing 1–30 μg of salmon sperm DNA. Particles were treated with EDTA, and the sample (20 μl) was submitted to agarose gel electrophoresis. Gels were stained with ethidium bromide and photographed over a UV trans-illuminator using a digital camera (FluorChem Q System, ProteinSimple).

**Proteomic analysis.** A washed particle specimen corresponding to each condition was resuspended in 50 mM EDTA and treated with a solution of 25 mM NH₄HCO₃ containing 10 mM dithiothreitol at 56 °C for 45 min. Samples were treated with 25 mM NH₄HCO₃ containing 55 mM iodoacetamide at 22 °C for 30 min. Proteins were digested with 20 μg/ml sequencing-grade porcine trypsin (Promega) at 37 °C overnight. The samples were desalted using a homemade desalting column, prior to drying in a vacuum centrifuge, and resuspension in 0.1% (w/v) formic acid. Samples were loaded into a reverse-phase liquid chromatography trap column (Agilent Technologies, Zorbax 300SB-C18). Peptide separation was performed using a 10-cm analytical C18 column (New Objective, 75 μm internal diameter). Elution was performed by gradually increasing the concentration of acetonitrile (ACN), starting with 2% (v/v) ACN in 0.1% formic acid and ending with 95% ACN. The column was coupled to a LTQ-Orbitrap mass spectrometer operated using the Xcalibur 2.0 software (Thermo Fisher Scientific). Proteomic analysis was performed as described earlier.

**Metabolomic analysis.** Ultra-performance liquid chromatography (UPLC) was performed using an Acquity BEH C18 column (Waters; 130 Å, 1.7 μm, 2.1 mm × 100 mm). Mass spectrometry was done using time-of-flight (TOF) Synapt HDMS system (Waters). UPLC-grade solvents were purchased from Fluka. Capillary and cone voltage were set at 3000 V (2000 V in ESI− mode) and 35 V, respectively. Desolvation gas flow rate was 700 l/h, and gas flow was maintained at 25 l/h. Desolvation and source temperatures were respectively set at 300 °C and 80 °C. LockSpray frequency was set at 0.5 sec and was averaged over 10 scans for correction. Metabolites were validated by comparing candidate MS spectra with that of metabolite standards (Sigma). Data analysis of a sample corresponding to each condition as well as compound identification were performed as before.

**Results**

We observed earlier that mineral NPs prepared by mixing calcium and phosphate ions into a cell culture medium (i.e., DMEM) containing a body fluid such as serum are similar to the mineral particles detected in the human body in terms of their size, morphology, structure and composition. We therefore used these mineral particles to determine the organic compounds that bind to biological particles in body fluids of animals and humans. We also examined specimens prepared without serum in order to assess the effects of the latter on particle formation. Under scanning electron microscopy (SEM), specimens prepared by adding calcium and phosphate into DMEM in the absence of serum-free mineral particles did not stain with any of these dyes (Fig. 1A–E; minor positive staining was attributed to the presence of proteins, lipids, polysaccharides, and DNA, respectively, within the particles. While serum-free mineral samples did not stain with any of these dyes (Fig. 2F–O). These results indicate that the main classes of organic compounds are present within the particles.

To confirm the binding of organic compounds to mineral particles, we prepared specimens in cell culture medium containing purified organic compounds. While serum-free specimens did not show any protein staining as assessed by SDS-PAGE, FBS-particles stained for proteins (Fig. 3A). Similarly, serum-free specimens prepared in the presence of albumin showed dose-dependent protein staining (Fig. 3A). Serum-free specimens and FBS-particles did not show the presence of the phosphoprotein phosphatidylethanolamine (PE) as assessed by thin-layer chromatography; however, FBS-particles prepared in the presence of PE showed dose-dependent PE staining (Fig. 3B). We also prepared mineral samples in the presence of the polysaccharide xanthan gum, and performed dot blots with biotinylated wheat germ agglutinin to determine the binding of the polysaccharide to the particles (Fig. 3C). While serum-free specimens and FBS-particles showed no detectable staining,
FBS-particles prepared in the presence of xanthan gum showed dose-dependent staining for the polysaccharide (Fig. 3C). Experiments were also performed to verify whether DNA bind to the mineral particles. Agarose gel electrophoresis showed that, as expected, serum-free samples prepared in the absence of DNA were not stained by ethidium bromide; however, FBS-particles and FBS-particles prepared in the presence of DNA showed positive staining (Fig. 3D). These results indicate that mineralo-organic particles bind to proteins, phospholipids, polysaccharides and DNA.

In order to determine the organic molecules that bind to the particles in a comprehensive manner, we submitted the particles to proteomics analysis. Following incubation and washing steps, the particles were resuspended in EDTA to release proteins. Various proteins were shown to bind to the mineral particles, including calcification inhibitors (i.e., fetuin-A, albumin), complement proteins (i.e., C3, C4-A), coagulation factors (i.e., factor X, prothrombin), glycoproteins (i.e., histidine-rich glycoprotein, vitronectin), apolipoproteins (i.e., A1, B-100, clusterin), and protease inhibitors (i.e., inter-α-trypsin inhibitor) (Table 1). While the proteins that bind to HS-particles and FBS-particles were similar, HS-particles harbored more proteins than FBS-particles (Table 1), possibly due at least in part to the higher concentration of proteins in HS (60 mg/ml) compared with FBS (32 mg/ml), as noted earlier.

We also performed a metabolomics analysis in order to identify the low-molecular weight compounds that bind to the mineral particles. Organic compounds released from the particles were resuspended in methanol and analyzed using reversed-phase UPLC-MS analysis. In the ESI+ mode, the compounds found to bind to the mineral particles included lyso-phosphatidylcholines (lysoPCs), monoacyl-glycerols (MGs), amides (i.e., lauroyl-diethanolamide, stearoyl-diethanolamide, niacinamide), carbohydrates (i.e., glucose) and amino acids (i.e., L-leucine, L-phenylalanine) (Table 2). In the ESI− mode, the organic compounds identified included mainly lysoPCs and fatty acids (i.e., stearic acid, palmitic acid, oleic acid, myristic acid, margaric acid, pentadecylic acid, palmitoleic acid, linolenic acid, 9-heptadecanoic acid, arachidic acid, docosahexaenoic acid) (Table 3).
HS-particles and FBS-particles interacted with the same organic compounds, variation in signal intensity was noted between these samples (Tables 2 and 3).

Discussion

Major advances have been made in the understanding of the protein corona which may influence the effects of NPs in the human body\textsuperscript{22,23}. On the other hand, it remained unclear whether other organic molecules may also bind to mineral NPs that form in body fluids. We describe here that the major classes of organic molecules, including proteins, sugars, lipids, polysaccharides and nucleic acids, bind to mineralo-organic particles derived...
from biological fluids. These organic molecules are likely to stabilize the formation of mineral particles and allow their transport in biological fluids, in a manner similar to what has been described earlier regarding the role of proteins in particle formation5,13. While earlier studies have shown that the particles prepared in vitro using the approach described in the present study are highly similar to the mineralo-organic particles detected in human tissues2–4,15, we could not exclude the possibility that minor differences may be observed between the organic molecules that bind to the prepared and isolated particles. Our results suggest that the binding of these organic compounds to particles may influence various physiological and pathological processes occurring in vivo, a possibility that remains to be examined in more details.

Table 1. Protein composition of serum-derived particles. Proteins were ranked based on the sum of emPAI and spectral counts (“spectra”) for HS-particles and FBS-particles. Accession numbers correspond to UniProt entries. MW, molecular weight; emPAI, exponentially modified protein abundance index.

| No. | Protein               | Accession No. | MW (kDa) | HS-Particles | FBS-Particles |
|-----|-----------------------|---------------|----------|--------------|---------------|
|     |                       | emPAI Spectra |          | emPAI Spectra |               |
| 1   | Fetuin-A              | P12763        | 38.39    |              | 1.1           | 103.9         |
| 2   | Complement C3         | P01024        | 187.03   | 0.17         | 21            |               |
| 3   | Albumin               | P02768        | 69.32    | 0.19         | 19.9          |               |
| 4   | Fetuin-A              | P02765        | 39.30    | 0.37         | 15.5          |               |
| 5   | Vitronectin           | P04004        | 54.27    | 0.17         | 10            |               |
| 6   | Inter-α-trypsin inhibitor heavy chain H2 | P19823 | 106.40 | 0.17          | 8.9          |               |
| 7   | Apolipoprotein B-100  | P04114        | 515.28   | 0.02         | 8.9           |               |
| 8   | Albumin               | P02769        | 69.25    |              | 0.35          | 8.2           |
| 9   | Prothrombin           | P00734        | 69.99    | 0.1          | 6.6           |               |
| 10  | Complement C4-A       | P00744        | 192.66   | 0.04         | 5.5           |               |
| 11  | Coagulation factor X  | P00745        | 54.48    |              |               | 0.3           |
| 12  | Coagulation factor X  | P00746        | 54.70    | 0.2          | 4.4           |               |
| 13  | Clusterin             | P10909        | 52.46    | 0.17         | 4.4           |               |
| 14  | Apolipoprotein A1     | P02647        | 30.76    | 0.09         | 4.4           |               |
| 15  | Histidine-rich glycoprotein | P04196 | 59.54 | 0.07         | 4.4           |               |
| 16  | α4b-binding protein α chain | P04003 | 66.99 | 0.06         | 4.4           |               |
| 17  | Serum amyloid A-4 protein | P35542 | 14.74 | 0.74         | 3.3           |               |
| 18  | Prothrombin           | P00735        | 70.46    |              | 0.12          | 3.6           |
| 19  | Prothromosin-α        | P01252        | 12.06    |              | 1             | 2.7           |
| 20  | Complement C3         | Q2UVX4        | 187.14   |              | 0.07          | 3.6           |
| 21  | α-1-Antitrypsin       | P00746        | 46.71    | 0.09         | 3.3           |               |
| 22  | Apafin                | P43652        | 69.02    | 0.06         | 3.3           |               |
| 23  | Serotransferrin       | Q29444        | 77.70    |              | 0.11          | 1.8           |

Table 2. Organic compounds bound to serum-derived particles and identified in the ESI+ mode. Numbers given within parentheses in the “Compound” column correspond respectively to the number of carbons and double bonds found in the fatty acid molecule. Compounds were ranked based on the ion intensity of FBS-particles. ESI, electrospray ionization; HMDB, Human Metabolome Database; ID, identification; MG, monoacylglycerol; PC, phosphatidylcholine; RT, retention time.

| #  | Compound                          | ID Number  | Formula                  | RT (min) | m/z       | FBS-Particles | HS-Particles |
|----|-----------------------------------|------------|--------------------------|----------|-----------|---------------|--------------|
| 1  | LysoPC (16:0)                     | HMDB10382  | C_{n}H_{2n+1}O_{7}P      | 2.09     | 496.3402  | 3639.3        | 18967.7      |
| 2  | MG (18:0)                         | HMDB11535  | C_{n}H_{2n+1}O_{7}P      | 2.57     | 359.3141  | 1389.6        | 1624.1       |
| 3  | MG (16:0)                         | HMDB11564  | C_{n}H_{2n+1}O_{7}P      | 2.41     | 331.2822  | 1096.1        | 815.7        |
| 4  | LysoPC (20:4)                     | HMDB10395  | C_{n}H_{2n+1}O_{7}P      | 1.94     | 544.3405  | 733.9         | 5835.1       |
| 5  | LysoPC (18:1)                     | HMDB02815  | C_{n}H_{2n+1}O_{7}P      | 2.10     | 522.3574  | 442.4         | 1019.3       |
| 6  | Glucose                           | HMDB06564  | C_{n}H_{2n+1}O_{7}Na     | 0.48     | 203.0523  | 312.6         | 645.6        |
| 7  | LysoPC (22:6)                     | HMDB10404  | C_{n}H_{2n+1}O_{7}P      | 1.91     | 568.3402  | 251.9         | 2374.4       |
| 8  | Lauroylthanolamide                | HMDB32358  | C_{n}H_{2n+1}O_{7}      | 1.84     | 288.2536  | 122.2         | 140.6        |
| 9  | Stearoylthanolamide               | HMDB13078  | C_{n}H_{2n+1}O_{7}      | 2.53     | 328.3184  | 105.9         | 101.2        |
| 10 | Choline                           | HMDB00097  | C_{n}H_{2n+1}O_{7}      | 0.52     | 104.1069  | 78.9          | 434.2        |
| 11 | Niacinamide                       | HMDB10406  | C_{n}H_{2n+1}O_{7}      | 0.84     | 123.0564  | 54.9          | 139.1        |
| 12 | L-Phenylalanine                   | HMDB00159  | C_{n}H_{2n+1}O_{7}      | 0.85     | 166.0867  | 47.7          | 154.7        |
| 13 | L-Leucine                         | HMDB00687  | C_{n}H_{2n+1}O_{7}      | 0.81     | 132.1022  | 38.6          | 65.2         |
Table 3. Organic compounds bound to serum-derived particles and identified in the ESI− mode. Numbers given within parentheses in the “Compound” column correspond respectively to the number of carbons and double bonds found in the fatty acid molecule. Compounds were ranked based on the ion intensity of FBS-particles. ESI, electrospray ionization; HMDB, Human Metabolome Database; ID, identification; DHA, docosahexaenoic acid; PC, phosphatidylcholine; RT, retention time.

| # | Compound | ID Number | Formula          | RT   | m/z   | FBS-Particles | HS-Particles |
|---|----------|-----------|------------------|------|-------|---------------|--------------|
| 1 | Stearic acid | HMDB00827  | C_{18}H_{36}O_{2} | 2.80 | 283.2628 | 15500.5       | 16917.9      |
| 2 | Palmitic acid | HMDB00220  | C_{16}H_{32}O_{2} | 2.50 | 255.2317 | 11803.8       | 14886.4      |
| 3 | Oleic acid | HMDB00207  | C_{18}H_{34}O_{2} | 2.51 | 281.2487 | 1593.3        | 4197.2       |
| 4 | Myristic acid | HMDB00806  | C_{14}H_{28}O_{2} | 2.27 | 227.2003 | 1503.0        | 411.6        |
| 5 | Margaric acid | HMDB02259  | C_{16}H_{30}O_{2} | 2.66 | 269.2479 | 1355.6       | 1698.2       |
| 6 | Pentadecyclic acid | HMDB00826  | C_{15}H_{30}O_{2} | 2.39 | 241.2156 | 1127.3       | 711.7        |
| 7 | Palmitoleic acid | HMDB03229  | C_{16}H_{32}O_{2} | 2.30 | 253.2159 | 624.6         | 548.1        |
| 8 | Limonie acid | HMDB00673  | C_{10}H_{20}O_{2} | 2.33 | 279.2325 | 331.4         | 6627.5       |
| 9 | 9-Heptadecencic acid | HMDB31046  | C_{17}H_{34}O_{2} | 2.40 | 267.2325 | 207.1         | 155.7        |
| 10 | Arachidic acid | HMDB02212  | C_{20}H_{42}O_{2} | 3.31 | 311.2954 | 206.8         | 179.6        |
| 11 | LysoPC (15:0) | HMDB10381  | C_{23}H_{48}O_{2} | 2.07 | 480.3085 | 199.1         | 839.4        |
| 12 | LysoPC (18:2) | HMDB10386  | C_{24}H_{48}O_{2} | 1.99 | 564.3322 | 101.5         | 1871.3       |
| 13 | DHA | HMDB61088  | C_{22}H_{36}O_{2} | 2.21 | 327.2322 | 77.2          | 1558.5       |

One of the major findings reported here is that mineralo-organic particles prepared in biological fluids bind to nucleic acids. These mineral-DNA complexes show similarities to virus particles in terms of their sizes and chemical composition. Mineral particles consisting of calcium phosphate are routinely used for transfection of DNA into eukaryotic cells in culture44. Calcium phosphate particles have also been used as gene-delivery vectors in vivo45. These observations suggest that cells may internalize mineralo-organic particles in the circulation and in tissues, possibly leading to transfer of DNA between host cells and other organisms, including the gut microbiota. It remains to be seen whether this phenomenon occurs in vivo and whether it may produce any effects on the cells and organs in the body.

We propose that the organic compounds found to bind to the mineralo-organic particles may serve as markers to detect and quantify the particles in human tissues and body fluids, as well as to study the formation and role of the biological particles in the human body. Accordingly, proteins such as albumin and fetuin-A have been shown to consistently interact with the mineral particles that form in biological fluids46,47. Spectroscopy analyses such as EDX and X-ray diffraction may thus be used in combination with enzyme-linked immunosorbent assay (ELISA), proteomics or metabolomics to detect mineralo-organic particles in biological specimens. Moreover, we expect that the methodology described here will also yield important information regarding the effects of mineralo-organic particles in the body.

Conclusion

Our results indicate that mineralo-organic particles that form in biological fluids bind to various organic compounds. The major families of organic molecules were all found to bind to the mineral particles, including proteins, lipids, polysaccharides and DNA. The profiling performed in the present study provides a platform to study the effects of such molecule-particle interactions in physiological and pathological processes occurring in the human body.

References

1. Martel, I. & Young, J. D. Purported nanobacteria in human blood as calcium carbonate nanoparticles. Proc Natl Acad Sci USA 105, 5549–5554 (2008).
2. Young, J. D. et al. Purputative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLOS ONE 4, e4417 (2009).
3. Young, J. D. et al. Characterization of granulations of calcium and apatite in serum as pleomorphic mineral-protein complexes and as precursors of putative nanobacteria. PLOS ONE 4, e3421 (2009).
4. Wu, C. Y., Martel, J., Young, D. & Young, J. D. Fetuin-A/albumin-mineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibition-seeding concept. PLOS ONE 4, e8058 (2009).
5. Young, J. D. & Martel, I. The rise and fall of nanobacteria. Sci Am 302, 52–59 (2010).
6. Martel, I., Wu, C. Y. & Young, J. D. Critical evaluation of gamma-irradiated serum used as feeder in the culture and demonstration of putative nanobacteria and calcifying nanoparticles. PLOS ONE 5, e10343 (2010).
7. Martel, I. et al. Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal Biochem 418, 111–125 (2011).
8. Peng, H. H., Martel, J., Lee, Y. H., Ojcius, D. M. & Young, J. D. Serum-derived nanoparticles: de novo generation and growth in vitro, and internalization by mammalian cells in culture. Nanomedicine (Lond) 6, 643–658 (2011).
9. Martel, I., Young, D., Peng, H. H., Wu, C. Y. & Young, J. D. Biomimetic properties of minerals and the search for life in the Martian meteorite ALH84001. Ann Rev Earth Planet Sci 40, 167–193 (2012).
10. Peng, H. H. et al. Physicochemical and biological properties of biomimetic mineralo-protein nanoparticles formed spontaneously in biological fluids. Small 9, 2297–2307 (2013).
11. Wu, C. Y. et al. Membrane vesicles nucleate mineralo-organic nanoparticles and induce carbonate apatite precipitation in human body fluids. J Biol Chem 288, 30571–30584 (2013).
12. Wu, C. Y., Young, L., Young, D., Martel, J. & Young, J. D. Bions: a family of biomimetic mineralo-organic complexes derived from biological fluids. PLOS ONE 8, e75501 (2013).
13. Martel, J., Peng, H. H., Young, D., Wu, C. Y. & Young, J. D. Of nanobacteria, nanoparticles, biofilms and their role in health and disease: facts, fancy, and future. *Nanomedicine (Lond)* **9**, 483–499 (2014).
14. Wu, C. Y., Young, D., Martel, J. & Young, J. D. A story told by a single nanoparticle in the body fluid: demonstration of dissolution-reprecipitation of nanocrystals in a biological system. *Nanomedicine (Lond)* **10**, 2659–2676 (2015).
15. Wong, T. Y. et al. Detection and characterization of mineralo-organic nanoparticles in human kidneys. *Sci Rep* **5**, 15272 (2015).
16. Wong, T. Y. et al. Nanoparticle conversion to biofilms: *in vitro* demonstration using serum-derived mineralo-organic nanoparticles. *Nanomedicine (Lond)* **10**, 3519–3535 (2015).
17. Martel, J. et al. Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. *Nanoscale* **8**, 5537–5545 (2016).
18. Martel, I., Wu, C. Y. & Young, J. D. Translocation of mineralo-organic nanoparticles from blood to urine: a new mechanism for the formation of kidney stones? *Nanomedicine (Lond)* **11**, 2399–2404 (2016).
19. Peng, H. H. et al. Mineral particles stimulate innate immunity through neutrophil extracellular traps containing HMGB1. *Sci Rep* **7**, 16628 (2017).
20. Powell, J. J. et al. An endogenous nanomineralcondensed chaperones luminal antigen and peptidoglycan to intestinal immune cells. *Nat Nanotechnol* **10**, 361–369 (2015).
21. Shook, L. L. et al. Calcioprotein particles as potential etiologic agents of idiopathic preterm birth. *Sci Transl Med* **8**, 364ra154 (2016).
22. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. *Nat Mater* **8**, 543–557 (2009).
23. Walkey, C. D. & Chan, W. C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. *Chem Soc Rev* **41**, 2780–2799 (2012).
24. Jordan, M., Schallhorn, A. & Wurm, F. M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. *Nucleic Acids Res* **24**, 596–601 (1996).
25. Roy, I., Mitra, S., Maitra, A. & Mozumdar, S. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. *Int J Pharm* **250**, 25–33 (2003).

**Acknowledgements**

The authors’ work is supported by the Primordia Institute of New Sciences and Medicine and by grants from Chang Gung Medical Research Projects (CLRDP1A0011, CLRDP1C0011-3 and QZRPD88E), Ming Chi University of Technology (0XB0), the Ministry of Education of Taiwan (EMRPD1B047), and the National Science Council of Taiwan (101-2632-B-182-001-MY3).

**Author Contributions**

C.-Y.W., J.M. and J.D.Y. designed experiments and analyzed data; C.-Y.W. performed experiments; J.M. and J.D.Y. wrote the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018